Viskase Holdings, Inc.

VISK ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Income Statement
Annual Quarterly

Income Statement

Line Item FY2015 FY2014 FY2013 FY2012 FY2011 FY2010 FY2009
Revenue $17.5M $31.2M $34.5M $42.6M $48.1M $97.9M $51.4M
Cost of Revenue — — — — — — —
Gross Profit — — — — — — —
Gross Margin — — — — — — —
Operating Expenses
Research & Development — $0 $2.7M $20.9M $40.2M $49.9M $45.6M
SG&A Expense — — — — — — —
Operating Income $10.8M $28.8M $18.2M $-4.0M $-16.5M $-575.0K $-57.1M
Operating Margin 61.9% 92.4% 52.6% -9.3% -34.2% -0.6% -111.1%
Interest Expense — $0 $2.1M $5.3M $5.9M $6.3M $11.5M
Pretax Income $10.8M $28.9M $18.1M $-6.9M $-20.6M $-3.1M $-59.3M
Income Tax Expense $-10.8M $56.0K $-28.0K $-4.1M $205.0K $-337.0K $-2.1M
Net Income $21.6M $28.8M $18.2M $-2.8M $-20.8M $177.2M $683.0K
Net Margin 124.0% 92.4% 52.6% -6.5% -43.2% 181.1% 1.3%
EPS (Basic) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
EPS (Diluted) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Shares Outstanding (Basic) 44.20B 44.13B 43.78B 46.74B 51.91B 58.82B —
Shares Outstanding (Diluted) 44.22B 44.25B 51.05B 46.74B 51.91B 58.82B —
Dividends Per Share $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 —
← Newer Page 2 of 2 Older →